FindTrial
Sign In

An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler and Pulmicort Respules in Japanese Asthmatic Adult Patients(Open, Multicenter, Phase III Study)

An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler and Pulmicort Respules in Japanese Asthmatic Adult Patients(Open, Multicenter, Phase III Study)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220694
Enrollment
Unknown
Registered
2009-03-17
Start date
2009-03-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : Budesonide Respules INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administratio

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Provision of informed consent prior to any study specific procedures -A minimum of 6 months documented history of asthma according to the JGL 2006 definition -Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2

Exclusion criteria

Exclusion criteria: -Current or previous tobacco smokers with a history of >= 10 pack-years -Use of beta-blockers including eye drops -Clinically significant respiratory infection affecting the asthma, as judged by the investigator(s) within 4 weeks prior to visit 2 -Intake of oral, rectal or parenteral GCS within 4 weeks prior to Visit 2

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026